BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27560010)

  • 1. Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid for Quantitative Assessment of Vascular Effects on Hepatocellular-Carcinoma Lesions Treated by Transarterial Chemoembolization or Radiofrequency Ablation.
    Ippolito D; Trattenero C; Talei Franzesi C; Casiraghi A; Lombardi S; Vacirca F; Corso R; Sironi S
    J Comput Assist Tomogr; 2016; 40(5):692-700. PubMed ID: 27560010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients.
    Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
    Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging?
    Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U
    J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
    Kamel IR; Bluemke DA; Eng J; Liapi E; Messersmith W; Reyes DK; Geschwind JF
    J Vasc Interv Radiol; 2006 Mar; 17(3):505-12. PubMed ID: 16567675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone.
    Kim JH; Kim PN; Won HJ; Shin YM
    AJR Am J Roentgenol; 2014 Nov; 203(5):1127-31. PubMed ID: 25341154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Otto G; Biesterfeld S; Oberholzer K; Dueber C; Pitton MB
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):532-40. PubMed ID: 19847482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization.
    Castrucci M; Sironi S; De Cobelli F; Salvioni M; Del Maschio A
    Abdom Imaging; 1996; 21(6):488-94. PubMed ID: 8875869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of magnetic resonance in the follow-up o hepatocarcinoma treated with percutaneous ethanol injection (PEI) or transarterial chemoembolization (TACE)].
    De Cobelli F; Castrucci M; Sironi S; Livraghi T; Venturini M; Salvioni M; Del Maschio A
    Radiol Med; 1994 Dec; 88(6):806-17. PubMed ID: 7878241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
    Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.
    Cho YZ; Park SY; Choi EH; Baik SK; Kwon SO; Kim YJ; Cha SH; Kim MY
    Clin Mol Hepatol; 2015 Jun; 21(2):165-74. PubMed ID: 26157754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study.
    Haochen W; Jian W; Li S; Tianshi L; Xiaoqiang T; Yinghua Z
    J Int Med Res; 2018 Jul; 46(7):2650-2657. PubMed ID: 29683022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma.
    Syha R; Grözinger G; Grosse U; Maurer M; Zender L; Horger M; Nikolaou K; Ketelsen D
    Invest Radiol; 2016 Feb; 51(2):121-6. PubMed ID: 26488373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
    Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
    Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.
    Frericks BB; Loddenkemper C; Huppertz A; Valdeig S; Stroux A; Seja M; Wolf KJ; Albrecht T
    AJR Am J Roentgenol; 2009 Oct; 193(4):1053-60. PubMed ID: 19770329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of therapeutic effectiveness of transarterial chemoembolization for hepatocellular carcinoma: correlation of dynamic susceptibility contrast-enhanced echoplanar imaging and hepatic angiography.
    Tsui EY; Chan JH; Cheung YK; Cheung CC; Tsui WC; Szeto ML; Lau KW; Yuen MK; Luk SH
    Clin Imaging; 2000; 24(4):210-6. PubMed ID: 11274885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma.
    El-Kady NM; Esmat G; Mahmoud EH; Darweesh SK; Mahmoud SH; Elagawy WA
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):628-33. PubMed ID: 23325283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viable residual tumor tissue after radiofrequency ablation treatment in hepatocellular carcinoma: evaluation with CT perfusion.
    Ippolito D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
    Abdom Imaging; 2013 Jun; 38(3):502-10. PubMed ID: 22743839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.